Industry News

October 2022
New Manufacturing Technology Platforms for Biosimilars

One of the main drivers for the pipeline growth in biosimilars is the number of originator blockbuster molecules coming off patent -17 blockbuster molecules with annual peak sales worth $60 billion have or will lose exclusivity between 2020 and 2025.

View PDF

November 2021
BioXpress Featured in European Pharmaceutical Contractor

European Pharmaceutical Contractor interviews Campbell Bounce at Abzena and Gerrit Hagens from BioXpress Therapeutics.

Visit E-Book Online